1022 |
CYCLIN DEPENDENT KINASE 7 |
CDK7 |
CAK |
CAK1 |
CDKN7 |
HCAK |
MO15 |
STK1 |
p39MO15 |
601955 |
1778 |
ENSG00000134058 |
OTTHUMG00000099358 |
P50613 |
cyclin-dependent kinase 7 |
p39 Mo15 |
39 kDa protein kinase |
CDK-activating kinase 1 |
Cell division protein kinase 7 |
Serine/threonine-protein kinase 1 |
TFIIH basal transcription factor complex kinase subunit |
CDK 1,2,4,5,6,7,9 (pan-CDK) |
CDK 2,7,9 |
CDK7_HUMAN |
CELL DIVISION PROTEIN KINASE 7 (EC 2.7.1.37) (CDK-ACTIVATING KINASE) (CAK) (TFIIH BASAL TRANSCRIPTION FACTOR COMPLEX KINASE SUBUNIT) (39 KDA PROTEIN KINASE) (P39 MO15) (STK1) (CAK1). [SOURCE:UNIPROT/SWISSPROT;ACC:P50613] |
T58449 |
Target Subclass | EC:2.7.11.22 |
Target Subclass | 2.7.11.23 |
Target Class | Enzymes |
CancerCommons Reported Gene Name | CDK2,7,9 |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ser/Thr_dual-sp_kinase_dom |
Uniprot Evidence | 1: Evidence at protein level |
Human Readable Name | DRUGGABLE GENOME |
Interpro Name | Serine/threonine- / dual-specificity protein kinase, catalytic domain |
Human Readable Name | KINASE |
Interpro Acc | IPR002290 |
Interpro Type | Domain |
Gene Biotype | PROTEIN_CODING |
TUMOR SUPPRESSOR |
DNA REPAIR |
KINASE |
SERINE THREONINE KINASE |
DRUGGABLE GENOME |
TRANSCRIPTION FACTOR |
inhibitor (inhibitory) |
Novel drug target | Novel Target |
Trial Name | seliciclib, R-roscovitine, CYC202 |
Mechanism of Interaction | Cyclin-dependent kinase 7 inhibitor |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Direct Interaction | yes |
Mechanism of Interaction | Cyclin-dependent kinase 7 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase 7 inhibitor |
Direct Interaction | yes |
Trial Name | flavopiridol, alvocidib, HMR-1275 |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase 7 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Cyclin-dependent kinase 7 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Cyclin-dependent kinase inhibitor |
CDK7 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ENSG00000134058 | Ensembl Gene Id |
1022 | Entrez Gene Id |
CDK7_HUMAN | Uniprot Id |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ser/Thr_dual-sp_kinase_dom |
Uniprot Evidence | 1: Evidence at protein level |
KINASE, DRUGGABLE GENOME |
CDK7 | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.22 |
Target Subclass | 2.7.11.23 |
CDK7 | Display Id |
ENSG00000134058 | Ensembl Gene Id |
CELL DIVISION PROTEIN KINASE 7 (EC 2.7.1.37) (CDK-ACTIVATING KINASE) (CAK) (TFIIH BASAL TRANSCRIPTION FACTOR COMPLEX KINASE SUBUNIT) (39 KDA PROTEIN KINASE) (P39 MO15) (STK1) (CAK1). [SOURCE:UNIPROT/SWISSPROT;ACC:P50613] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
1022 | Entrez Gene ID |
CancerCommons Reported Gene Name | CDK2,7,9 |
ENSG00000134058 | Gene Symbol |
CDK7 | Ensembl Id |
DRUGGABLE GENOME |
1022 | Entrez Gene Id |
CDK7 | MyCancerGenome Gene Symbol |
CDK 1,2,4,5,6,7,9 (pan-CDK) | MyCancerGenome Reported Gene Name |
CAK1 | GENE_SYMBOL |
CDKN7 | GENE_SYMBOL |
MO15 | GENE_SYMBOL |
CAK | GO Gene Synonym |
CAK1 | GO Gene Synonym |
CDKN7 | GO Gene Synonym |
TUMOR SUPPRESSOR, DNA REPAIR, SERINE THREONINE KINASE |
1022 | Gene ID |
CAK1 | dGene Synonym |
CDKN7 | dGene Synonym |
KINASE, SERINE THREONINE KINASE |
CDK7 | TTD Gene Abbreviation |
T58449 | TTD Target ID |
Cyclin-dependent kinase 7 | Gene Name |
P50613 | UniProt ID |
KINASE, TRANSCRIPTION FACTOR |